Cole, Alice;
Denton, Christopher P;
(2022)
Biomarkers in Systemic Sclerosis Associated Interstitial Lung Disease (SSc-ILD).
Current Treatment Options in Rheumatology
10.1007/s40674-022-00196-3.
(In press).
Preview |
Text
Denton_Biomarkers in Systemic Sclerosis Associated Interstitial Lung Disease (SSc-ILD)_AOP.pdf - Published Version Download (932kB) | Preview |
Abstract
PURPOSE OF REVIEW: Interstitial lung disease (ILD) is the leading cause of mortality in systemic sclerosis, a rare autoimmune disease characterised by fibrosis and vasculopathy. The variety of phenotypes in SSc-ILD have inspired multiple studies aimed at the identification of biomarkers which can provide disease-specific information but due to the complex pathogenesis of SSc-ILD, it has been challenging to validate such markers. We provide a comprehensive update on those most studied along with emerging biomarkers. RECENT FINDINGS: We review the up-to-date findings with regard to the use of well-studied molecular biomarkers in SSc-ILD along with novel biomarkers offering promise as prognostic markers such as IGFBP-2 and IGFBP-7, the adipokine CTRP9, endothelial progenitor cells, and cellular markers such as CD21lo/neg B cells. Expression profiling data is being used in SSc patients to determine genetic and epigenetic clusters which shed further light on mechanisms involved in the pathogenesis of SSc-ILD and are likely to uncover novel biomarkers. SUMMARY: With the exception of autoantibodies, there are no routinely measured biomarkers in SSc-ILD and reliable validation of the many potential biomarkers is lacking. Identifying biomarkers which can offer diagnostic and prognostic certainty may help patients to receive preventative treatment as part of a personalised medicine approach.
| Type: | Article |
|---|---|
| Title: | Biomarkers in Systemic Sclerosis Associated Interstitial Lung Disease (SSc-ILD) |
| Open access status: | An open access version is available from UCL Discovery |
| DOI: | 10.1007/s40674-022-00196-3 |
| Publisher version: | https://doi.org/10.1007/s40674-022-00196-3 |
| Language: | English |
| Additional information: | This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. |
| Keywords: | Systemic sclerosis, Interstitial lung disease, Krebs von Lungen-6, Surfactant protein-D and chemokine ligand-18, Biomarkers |
| UCL classification: | UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Div of Medicine > Inflammation UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Div of Medicine |
| URI: | https://discovery.ucl.ac.uk/id/eprint/10157129 |
Loading...
Loading...Loading...Loading...Archive Staff Only
 |
View Item |
